The automatic implantable defibrillator: local ventricular bipolar sensing to detect ventricular tachycardia and fibrillation

Michel Mirowski and the beginning of a new era of fighting sudden arrhythmic death

Prior to the implantable cardioverter-defibrillator (ICD), life-threatening ventricular arrhythmias were treated using anti-arrhythmic drugs. The concept of an implantable defibrillator to prevent sudden arrhythmic death was first published by Michel Mirowski in 1970. Despite critical opinions by leading physicians, Michel Mirowski continued development of his vision. Hallmarks in the development of the ICD include the following: internal-external defibrillator used during surgery on humans in 1971/1972; fully implantable defibrillator tested in canines in 1975; defibrillator successfully implanted in a 57-year-old woman in 1980; second generation devices introduced in 1982; US Food and Drug Administration device approved in 1985. Today it is hard to imagine modern medicine without ICD therapy. This article provides the reader a history of the development of the ICD.

Development and Industrialization of the Implantable Cardioverter-Defibrillator: A Personal and Historical Perspective

The implantable cardioverter-defibrillator (ICD) is the standard of care for preventing sudden cardiac death. Contemporary ICDs are capable of providing a variety of therapeutic functions and can automatically gather and store diagnostic data that can guide both device and drug therapy and alert caregivers of impending battery depletion or lead problems. Moreover, much of the diagnostic data can be monitored remotely, so that many patients can be evaluated in their homes. This article, by a former chief executive officer of the first company to commercialize the ICD, traces the history of the device from its beginnings in the early 1980s.

Implantable Cardioverter Defibrillator: Current Progress and Management

With greater technologic advances during the past decade, use of the implantable cardioverter defibrillator (ICD) has increased to more than 200,000 implants worldwide to date. Indications for ICD implant have expanded to include both patients who have survived sudden cardiac death (secondary prevention of cardiac arrest) and those who are at high risk for experiencing lethal arrhythmias (primary prevention of cardiac ar rest). Thus, it is likely that physicians will encounter defibrillators in their clinical practice and must be familiar with their indications for implant, basic opera tion, and long-term management of devices. Several prospective clinical trials have recently shown the long- term efficacy of ICD therapy at aborting sudden death in the high-risk patient population. Although still evolving, general guidelines and indications for ICD implant have been put forth and are discussed in this review. From the first defibrillation in humans during surgery in 1947 to the sophisticated dual-chamber pacing and memory functions of the modern device, ICD development has led to ever smaller devices with more complex technol ogy. The implant procedure of current ICDs parallels that used to place pacemakers. However, the anesthe sia team plays a vital role in initial ICD implantation by monitoring cardiopulmonary status during defibrilla tion threshold (DFT) testing. Additionally, long-term management of ICDs often requires repeat DFT testing with anesthesia involvement. Finally, possible electro magnetic (environmental) interactions with the ICD of which physicians should be aware are described in this article.

Dual level sensing significantly improves automatic threshold control for R wave sensing in implantable defibrillators. The Angeion Corporation

ICDs must sense R waves over a range of amplitudes without sensing P or T waves. Automatic threshold control (ATC) is an accepted sensing method for that task. ATC sensing levels are from 25%-75% of the electrogram (EGM) peak, decreasing with an exponential decay. A high sensing level for a time after peak detection may better allow ATC to pass over a T wave, while a lower sensing level thereafter may better allow ATC to sense the next R wave. An ATC was designed with two sensing levels and time constants (tau), using a 58% level (tau = 1.75 s) for 325 ms after peak detection switching to 33% (tau = 1.1 s) thereafter, and was compared to a single level ATC (sensing level = 50%, tau = 1.4 s). The two ATC circuits were tested with 22 arrhythmia EGMs to determine sensitivity and specificity rates at +/-1-, 2-, 5-, 10-, and 20-mV amplitudes. It was confirmed that a dual level ATC significantly improves the sensitivity rate without degrading the high specificity rate of a standard sensing circuit.

Changes in the amplitude of endocardial electrograms following defibrillator discharge: comparison of two lead systems

Changes in the amplitude of endocardial electrograms after an unsuccessful shock attempt have been demonstrated to cause failure of redetection of ventricular fibrillation in patients using an integrated sense-pace defibrillating lead system. Thus, the objective of this study was to compare the effects of defibrillator shocks on the amplitude of endocardial electrograms in 26 patients using two different nonthoracotomy systems, a previous lead (model 0062) or a redesigned version (model 0072). At implant, bipolar endocardial electrograms were obtained before each shock application, during initial detection and redetection of ventricular fibrillation in case the applied shock was unsuccessful, and during intervals of 5, 10, 20, 30, 60, and 120 seconds after each shock delivery. No significant difference was noted in endocardial amplitudes between the lead models 0062 and 0072 during baseline sinus rhythm (12.2 +/- 4.6 mV vs 11.4 +/- 3.8 mV), and during initial ventricular fibrillation (7.0 +/- 2.4 mV vs 7.6 +/- 2.3 mV). During redetection of ventricular fibrillation, however, there was a significant difference (P = 0.0006) in endocardial amplitudes (3.4 +/- 1.9 mV vs 6.6 +/- 2.3 mV) between both leads tested. Comparing lead models 0062 and 0072, marked differences were found in endocardial amplitudes during sinus rhythm 5, 10, and 20 seconds after successful arrhythmia termination: 2.8 +/- 1.9 mV vs 8.6 +/- 2.9 mV (P < 0.0001), 4.6 +/- 2.9 mV vs 9.2 +/- 3.2 mV (P = 0.0007), and 6.4 +/- 4.0 mV vs 10.5 +/- 3.6 mV (P = 0.01). At predischarge testing, failure of redetection of ventricular fibrillation was documented in two patients with the lead model 0062 requiring external defibrillation to restore sinus rhythm. These findings demonstrate a significant less postshock attenuation of the endocardial electrogram amplitudes during persistent ventricular fibrillation after an unsuccessful shock attempt as well as during sinus rhythm immediately following an effective shock delivery using the redesigned lead system model 0072 compared to the electrogram amplitudes obtained in patients using the previous lead model 0062.

Adequacy of implantable cardioverter-defibrillator lead placement for tachyarrhythmia detection by sinus rhythm electrogram amplitude

This study examines whether the current clinical practice of using a 5 mV minimum amplitude during normal sinus rhythm (NSR) ensures adequate detection during subsequent episodes of ventricular fibrillation (VF) at the time of the implantable cardioverter-defibrillator (ICD) threshold testing. Risk of nondetection occurs with ICDs when a substantial portion of the individual cardiac events on an electrogram goes undetected. Detection risk was assessed by 2 methods: percentage of missed cardiac events (incidence of signal dropout), and mean electrogram amplitude. During ICD implantation and testing in 27 patients utilizing 41 lead positions, 135 episodes of VF were induced and analyzed. On 64 occasions, the countershock was not successful in achieving cardioversion, and the continuing electrical activity was analyzed as a separate group of postshock waveforms. Thresholds of 1 and 2 mV were applied to each individual cardiac depolarization in a VF episode. Significant risk of nondetection was assumed when > or = 10% of individual events displayed dropout. Underdetection by signal dropout occurred in 11 of 135 preshock arrhythmia signals (8.1%) from 3 patients at a 2 mV threshold, and in 6 of 135 signals (4.4%) at a 1 mV threshold. A mean NSR amplitude > or = 5 mV was associated with significantly lower risk of nondetection during subsequent VF episodes at both 1 and 2 mV thresholds (largest p < 0.001). Similar results were observed in analysis of postshock arrhythmia signals. Further examination of signal dropout and linear regression criteria suggest that in order to eliminate the possibility of nondetection at a 1 mV threshold, minimum NSR amplitudes of 8.5 and 10.0 mV, respectively, are required.

Future developments in implantable cardioverter defibrillators: the optimal device

Despite recent therapeutic advances, SCD remains the leading cause of mortality in industralized nations. The most frequent cause of SCD is ventricular tachyarrhythmias in the setting of advanced structural heart disease due to chronic coronary heart disease or idiopathic dilated cardiomyopathy. Although high-risk groups can be prospectively identified, attempts at primary prevention have been largely unsuccessful. Effective treatment strategies for SCD survivors include antiarrhythmic drug therapy guided by programmed stimulation, endocardial resection, and ICDs. Device therapy has proven extremely effective in preventing recurrent sudden death from ventricular tachyarrhythmias. Widespread application of ICD therapy, perhaps even to include members of high-risk populations that have not experienced cardiac arrest, will depend on many factors including the demonstration that device therapy improves total mortality, not just arrhythmia-related mortality, reduction in cost, and improvements in the devices themselves. Some of the important characteristics of the optimal ICD of the future are nonthoracotomy lead placement; subpectoral generator placement; multiprogrammable, tiered therapy; improved diagnostic specificity, whether based on electrogram or hemodynamic-sensing algorithms; improved integration of brady- and tachy-sensing systems; and enhanced electrogram storage capability with trans-telephonic retrieval of electrogram recordings. The creation of this ideal ICD will obviously require continued technological advances; however, given the tremendous improvements realized over the first three generations of ICD systems, optimism for the future seems warranted.

Implantable cardioverter defibrillator: the role of thoracoscopy

Video techniques have been used in many centers to assist with pericardial patch placement for implantable defibrillators. Although there are some specific instances where this technique would be helpful, the success of the transvenous systems will limit the application of this approach.

Clinical results with nonthoracotomy ICD systems

The results of two separate US Food and Drug Administration clinical trials that involved endocardial and epicardial leads were compared with regard to patient demographics, detection and conversion characteristics, and subsequent clinical course including long-term survival experience. The patient groups, although not strictly contemporaneous, were sufficiently similar to allow meaningful comparisons. There were no significant differences in detection of induced arrhythmias and ability to convert them. The surgical mortality, infection rate, and incidence of other morbid complications were lower in patients who had received endocardial leads; however, the differences did not reach statistical significance. Survivals through 1 year of follow-up were uniformly high. These results suggest that the performance of the endocardial lead system is comparable to existing epicardial leads in similar patient populations.

The performance of the probability density function in differentiating supraventricular from ventricular rhythms

The ability of the probability density function (PDF) of an automatic implantable cardioverter defibrillator (AICD) to reject supraventricular arrhythmias being recognized as ventricular was evaluated in 12 patients who were treated with an AICD (Ventak P 1600). The PDF criterion was monitored via telemetry with the sinus rate during exercise test. PDF was satisfied in seven patients at a rate of 75-144/min (mean 109/min), and not in the remaining five patients (mean rate 141/min). PDF was fulfilled in five of ten patients at a lower heart rate than predicted by the duty cycle index, derived from the ventricular patch lead electrogram at the implantation. Thus PDF is often fulfilled already at a moderately elevated sinus rate. If used to prevent inadvertent AICD discharges during rapid supraventricular rhythms, its performance should be tested in the individual patient.

Clinical experience with a tiered-therapy, multiprogrammable antiarrhythmia device

BACKGROUND

The purpose of this report is to describe our initial experience with a tiered-therapy, variable detection criteria, multiprogrammable antiarrhythmia device capable of antitachycardia pacing, cardioversion, and defibrillation in 50 cardiac arrest survivors.

METHODS AND RESULTS

An epicardial lead system was used in 35 patients. A transvenous lead system was used in 15 patients. The index arrhythmia leading to device implantation was ventricular fibrillation (VF) in 23 patients, ventricular tachycardia (VT) in 21 patients, and both VT and VF in six patients. Postoperatively, all 50 patients benefited from the additional functions available in the new device compared with a device capable only of high-energy termination of arrhythmias using a simple rate detection algorithm. Total patient survival over a mean follow-up period of 15 +/- 5 months was 96%, with no patient succumbing to sudden arrhythmic death, cardiac death, or surgical death. Nine patients (18%) avoided the need for a bradycardia pacemaker because of the device's backup bradycardia pacing function. A programmable tachycardia cycle length stability algorithm prevented inappropriate device intervention into atrial fibrillation in 11 patients (22%). Detection schema flexibility, antitachycardia pacing capabilities, and low-energy cardioversion options allowed the elimination or avoidance of antiarrhythmic drugs in 41 patients (82%). Device data storage facilitated troubleshooting and reprogramming of detection algorithms and therapeutic schema in all 50 patients. Finally, the ability to perform noninvasive programmed electrical stimulation obviated the need for invasive cardiac catheterization in 35 of 35 patients who required electrophysiological testing after device implantation.

CONCLUSIONS

These findings indicate that a multiprogrammable antiarrhythmia device can provide a substantial advance in the treatment of patients with disabling or life-threatening ventricular arrhythmias by minimizing the use of painful shocks, reducing the need for antiarrhythmic drugs, lowering the incidence of inappropriate shocks, facilitating electrophysiological evaluation, and obviating the need for dual-device therapy.

A hemodynamically responsive antitachycardia system. Development and basis for design in humans

Current automatic implantable cardioverter-defibrillators detect tachyarrhythmias primarily by rate-only algorithms and cannot adequately distinguish hemodynamically stable from unstable tachyarrhythmias. The responses of right atrial (mean) and right ventricular pressures (mean, systolic, diastolic, and pulse) to 64 induced and paced supraventricular and ventricular tachyarrhythmias were studied in 10 patients (left ventricular ejection fraction of 32 +/- 6%) to develop an algorithm capable of differentiating stable from unstable rhythms. Tachyarrhythmias were defined as hemodynamically unstable when mean arterial pressure decreased by 25 mm Hg or more during 15 seconds. Mean right atrial, right ventricular systolic, and right ventricular pulse pressures were found to be useful in distinguishing the hemodynamic significance of a tachyarrhythmia. A combined detection algorithm was developed that identified a hemodynamically unstable rhythm when the heart rate was 150 beats/min or more and mean right atrial pressure increased by 4 mm Hg or more and right ventricular systolic pressure decreased by 5 mm Hg or more during 15 seconds. This algorithm was then applied to the next 20 consecutive patients (left ventricular ejection fraction of 34 +/- 4%) and compared with the current rate-only algorithm (heart rate of 150 beats/min or more) in 143 tachyarrhythmias, and the sensitivity and specificity for detection of hemodynamically unstable tachyarrhythmias were determined. The rate-only detection algorithm had 100% sensitivity but only 68% specificity for detection of unstable tachyarrhythmias, whereas the combined rate-mean right atrial pressure-right ventricular systolic pressure detection algorithm had sensitivity and specificity of 100%. Therefore, the performance of an antitachycardia system may be significantly improved by detection algorithms that integrate hemodynamic and rate criteria.

Right ventricular pressure during ventricular arrhythmias in humans: potential implications for implantable antitachycardia devices

Implantable defibrillators use algorithms based on ventricular electrographic data to detect the onset and termination of arrhythmias, but these algorithms do not always differentiate hemodynamically stable from unstable arrhythmias. Although, ideally, left ventricular function should be used to assess the hemodynamic state, right ventricular pulse pressure can be assessed in humans on a long-term basis with a transvenous lead. The potential utility of right ventricular pulse pressure to assess hemodynamic stability was studied in 22 patients with induced ventricular arrhythmias. Right ventricular pressure was measured with use of a transvenous right ventricular endocardial pacing lead with a piezoelectric bender pressure sensor 3 cm from its tip. Single ventricular premature paced beats administered in up to a bigeminal frequency did not alter the mean right ventricular pulse pressure (control 33.7 +/- 26, bigeminy 35.7 +/- 26 mm Hg). Twenty-one episodes of induced ventricular tachycardia were studied in the electrophysiology laboratory. Five seconds after tachycardia induction, hemodynamically stable ventricular tachycardia had a longer cycle length (294 +/- 41 ms) and the right ventricular pulse pressure ratio was higher (0.55 +/- 0.26) than that in unstable ventricular tachycardia (cycle length 256 +/- 55 ms, p = 0.06; pulse pressure ratio 0.26 +/- 0.09, p less than 0.05). Twenty episodes of ventricular fibrillation were induced in eight patients. One second after induction, right ventricular pulse pressure decreased from 25 +/- 5 to 6 +/- 3 mm Hg (p less than 0.05). On the first beat after defibrillation, right ventricular pulse pressure increased to 24 +/- 14 mm Hg, a level not significantly different from that before the induction of ventricular fibrillation.(ABSTRACT TRUNCATED AT 250 WORDS)

A prospective, randomized evaluation of effect of ventricular fibrillation duration on defibrillation thresholds in humans

The effect of ventricular fibrillation duration in humans on defibrillation efficacy as it pertains to the time of intervention of an automatic implantable defibrillator is unknown. If a difference in defibrillation efficacy exists in the early period after ventricular fibrillation onset, it may affect algorithms used by antiarrhythmic devices for arrhythmia detection and therapy. Therefore, a prospective, randomized evaluation was performed of the effect of ventricular fibrillation durations of 10 s and 20 s on defibrillation thresholds in 10 survivors of sudden cardiac arrest undergoing implantation of an automatic cardioverter defibrillator. The initial duration of ventricular fibrillation was chosen randomly. Subsequently, each patient served as his or her own control for the alternate duration of ventricular fibrillation to that chosen initially. The mean leading edge defibrillation threshold voltage was 411 +/- 114 V when ventricular fibrillation persisted for 10 s and 419 +/- 125 V when it persisted for 20 s (p = 0.73). The mean defibrillation threshold current was 11.4 +/- 2.8 A when ventricular fibrillation persisted for 10 s and 11.4 +/- 3.2 A when it persisted for 20 s (p = 0.97). The delivered energy defibrillation threshold was 11.5 +/- 5.9 J when ventricular fibrillation persisted for 10 s and 12.0 +/- 6.9 J when it persisted for 20 s (p = 0.67). These findings show that the defibrillation threshold does not change between 10 and 20 s of ventricular fibrillation in out-of-hospital survivors of cardiac arrest at the time of surgical implantation of an automatic defibrillator. The data may have influence on the programming of defibrillator detection algorithms.

Implantable defibrillation: eight years clinical experience

Implantation of the first automatic defibrillator occurred in February 1980. Incorporation of cardioversion capability in 1982 resulted in the AICD automatic implantable cardioverter defibrillator. Between April 1, 1982 and April 15, 1988, 3610 patients in 236 U.S. and 84 international centers received AICD pulse generators. Patient population consisted of 2904 males and 683 females with recurrent ventricular tachycardia and/or fibrillation, mean age 59 yrs. (range 9-96 yrs.). Primary diagnoses reported for the patient group were: coronary artery disease (63.5%), nonischemic cardiomyopathy (12.9%), other (6.4%) and unspecified (17.2%). Mean reported LV ejection fraction was 32.8%. Follow-up averaged 12.2 mo. (range 0-72 mo.). Of 385 deaths, 94 (24%) were sudden. Cumulative percentage survival (+/- S.E.) from sudden cardiac death (SCD) was 98.0 +/- 0.3%, 96.5 +/- 0.5%, 95.2 +/- 0.7%, 93.7 +/- 1.0%, 93.7 +/- 1.0% and 89.7 +/- 4.0% at 12, 24, 36, 48, 60 and 72 months, respectively. Operative mortality (less than or equal to 30 days) was 2.5%. Reported side effects/complications were similar to those of pacemakers. To date, 33% of the patients received spontaneous device countershocks. AICD pulse generator survival from electrical and mechanical failures was 92.8 +/- 0.5%, 88.4 +/- 0.7%, 86.7 +/- 0.8% and 86.4 +/- 0.9% at 12, 18, 24 and 30 mos. Data analysis demonstrates that the AICD has had a significant impact on patient survival from SCD.

AICD indications (patient selection): past, present and future

During the course of a seven year implant experience with the Automatic Implantable Cardioverter-Defibrillator (AICD) now extending to well over 3,700 implantees, several functional advances have been made in the pulse generators, and criteria for implantation were successively broadened. Survival statistics have been excellent with 1-year arrhythmic survival over 98%, and total survival from all causes of death in excess of 60% at 5 years. Still, only relatively few of the patients who could possibly be helped by this device actually receive one. Reasons for this are probably complex but include, among other things, the relative newness of electrophysiology as a subspecialty, and a lack of appreciation by the general medical public in regard to this particular treatment modality. Small increases in referral patterns thus can have the potential to produce marked increases in the utilization of AICDs. Additionally, other high risk populations appear to be ready for inclusion into AICD therapeutic trials, and techniques also appear at hand to examine presumably healthy populations so as to predict those subject to suffer eventual sudden cardiac arrest. Under such circumstances, the ultimate impact of AICD therapy can hardly be imagined.

Influence of ventricular fibrillation duration on defibrillation energy in dogs using bidirectional pulse discharges

The automatic implantable defibrillator device typically discharges 5-30 seconds after detection of ventricular fibrillation. To investigate the importance of the duration of ventricular fibrillation on defibrillation, the effects of ventricular fibrillation durations of 5, 15, and 30 seconds on the energy requirements for successful internal defibrillation were compared in 15 closed chest dogs with internal electrodes. The electrode configuration utilized a transvenous right heart catheter with two electrodes and a precordial subcutaneous patch electrode, with a single bidirectional pulse discharged between the distal catheter electrode and the proximal catheter and patch electrodes. Curves of energy vs. percentage of successful defibrillation were constructed and logistic regression was used to derive 90% and 50% successful energy doses (ED90 and ED50). The mean ventricular fibrillation activation interval just prior to defibrillation was determined from discrete RV endocardial electrograms. Four dogs died during testing, all because of inability to defibrillate after 30 s of ventricular fibrillation. In the remaining 11 dogs, the ED90 increased from (mean +/- SD) 27 +/- 13J at 5 s to 41 +/- 14J at 30 s (p less than .01). The mean ventricular fibrillation activation interval decreased from 107 +/- 21 ms at 5 s to 95 +/- 18 ms at 30 s (p less than .01). In conclusion, the energy required for internal defibrillation in dogs using this electrode configuration increases with longer durations of ventricular fibrillation, and is associated with more rapid ventricular fibrillation activation intervals.

Computer discrimination of atrial fibrillation and regular atrial rhythms from intra-atrial electrograms

Reliable detection of atrial fibrillation from intra-atrial data is an important requirement for automatic implantable anti-tachycardia devices. Simultaneous filtered and unfiltered intra-atrial electrograms were recorded from patients in regular rhythms (12 sinus rhythms and six regular atrial tachycardias) and atrial fibrillation (nine rhythms). Each rhythm was broken down into consecutive 4-second data segments for analysis by atrial rate calculation, power spectrum analysis and amplitude probability density function generation. Significant differences were found between regular rhythms and atrial fibrillation for atrial rate, for the percentage of the total power in the 4-9 hertz band and for amplitude probability density close to the isoelectric region. There was no overlap for any of these three parameters. For each method of analysis, algorithms were generated to discriminate individual data segments from regular rhythms and atrial fibrillation with high sensitivity and specificity. Comparable results were found when sinus rhythm was excluded from the analysis. Characteristics of intra-atrial recordings during atrial fibrillation were remarkably similar to previously published reports of intra-ventricular recordings during ventricular fibrillation. Each of the three methods of analysis may provide an algorithm for accurate detection of atrial fibrillation by anti-tachycardia devices.

The automatic implantable cardioverter/defibrillator: transesophageal atrial pacing discloses the potential for erroneous discharges

We report the occurrence of erroneous discharge from an implanted automatic cardioverter/defibrillator during transesophageal atrial pacing. Transesophageal pacing was performed as part of a study protocol on the inducibility of ventricular tachycardia from the atrium in patients with ischemic heart disease. At an induced heart rate of 166 beats per minute (a value just above the cut-off rate of the device), the cardioverter/defibrillator was triggered. This observation suggests that transesophageal atrial pacing could be utilized to disclose the potential for spurious discharges in the event of fast atrial rhythms in patients with the automatic implantable cardioverter/defibrillator.

Sensing aberration by the automatic implantable cardioverter defibrillator during intraoperative testing

A 50-year-old man underwent replacement of his automatic implantable cardioverter defibrillator (AICD) because a magnet test revealed severe battery depletion. He had had his unit implanted 18 months previously after an episode of sudden cardiac death. He had documented torsades de pointes and inducible ventricular tachycardia, confirmed by electrophysiologic study. Before a new unit was implanted thresholds were measured by an external cardioverter defibrillator. Ventricular fibrillation (VF) was induced by alternating current through a standard, line-operated battery charger with stimulation delivered to the epicardium via rate-sensing electrodes. VF was allowed to continue for 10 seconds before shock was delivered. Termination of VF required 15 joules, which was higher than that required at initial implantation 18 months earlier. The new pulse generator was activated for testing and VF was again induced. The AICD discharged after 12.3 seconds. Prior to wound closing, the AICD was deactivated by magnet. Instead of R-wave synchronous beeping tones during deactivation, double beeping tones were heard. Electrogram recordings revealed abnormalities of the T-wave and ST segment of the rate-sensing electrodes, which were the cause of the tone irregularities. Stabilization of the T-wave and ST segment occurred within 8 minutes and the tones became normal. The procedure was then completed.

Effect of electrophysiological testing on ejection fraction during cardioverter/defibrillator implantation

To evaluate the effect of repeated induction of ventricular tachycardia or ventricular fibrillation, or both, in patients with poor left ventricular function, we performed intraoperative two-dimensional echocardiography in 6 patients undergoing implantation of the automatic implantable cardioverter/defibrillator. Changes in left ventricular ejection fraction in sinus rhythm were assessed before the first inducible ventricular arrhythmia and after a mean of 6 +/- 1.9 (SD) episodes of ventricular tachycardia or ventricular fibrillation. During the procedure no significant change in mean ejection fraction was observed (28 +/- 14 versus 27 +/- 17%). Only 1 of the 6 patients studied had a change in ejection fraction greater than 3% (a decrease from 20 to 11%). In an overall clinical series of 38 primary implants or generator changes (including electrophysiological testing) in 29 patients, 1 patient recovered after postoperative inotropic support and 1 died of acute postoperative ischemic heart failure. We conclude that ventricular arrhythmias induced during automatic implantable cardioverter/defibrillator implantation have no immediate deleterious effects on ejection fraction in most patients with compromised left ventricular function and without ongoing ischemia.

Automatic methods for detection of tachyarrhythmias by antitachycardia devices

Electrical devices play an increasingly important role in the control of tachyarrhythmias. Antitachycardia pacing and automatic defibrillation have been severely limited by the poor specificity of tachycardia discrimination in commercially available devices. Although absolute heart rate has been the principal means of automatic diagnosis, several new detection algorithms and methods are being investigated. Multiple electrode timing comparison, signal processing and pattern recognition are employed in these newer techniques. Although each offers some improvement over present technology, none is capable of identifying all arrhythmias. The methods employing comparison of atrial and ventricular rates, without additional criteria, are unable to detect ventricular tachycardia in the presence of 1:1 retrograde conduction. Electrographic analysis techniques require very stable electrodes and may not tolerate normal morphologic variations. A combination of two or more approaches may ultimately be required. All techniques will require that certain critical variables be programmable to allow for individualization in each clinical situation. Soft-ware-controllable devices and those capable of sensing from both the atria and the ventricles will provide the sophistication necessary for the implementation of complex tachycardia detection algorithms. This report reviews automatic tachycardia detection techniques in current use and under investigation.

Nonpharmacologic treatment of life-threatening cardiac arrhythmias

Numerous nonpharmacologic modalities have been introduced for the management of patients with life-threatening arrhythmias. These include cardiac pacing, insertion of an automatic internal cardiac defibrillator (AICD), cardiac electrosurgery, and catheter ablative techniques. Each modality is effective; AICD shows particular promise because it has demonstrated remarkable efficacy in decreasing the incidence of sudden cardiac death in patients with malignant ventricular arrhythmias. Each modality also has its limitations or contraindications. Nonpharmacologic antiarrhythmic therapy represents an important advance against the serious public health problem of sudden cardiac death.

Combination of antitachycardia pacemaker and automatic implantable cardioverter/defibrillator for ventricular tachycardia

Antitachycardia pacing for ventricular tachycardia (VT) is associated with the possibility of fibrillating the heart; on the other hand, the frequency of VT and patient discomfort can limit treatment with the automatic implantable cardioverter/defibrillator (AICD). To contribute to the further development of a universal pacemaker, we evaluated the combined use of the antitachycardia pacemaker ("tachylog") and the AICD in five patients with recurrent VT. In the automatic mode, the "tachylog" worked as a bipolar VVI pacemaker. For antitachycardia pacing, a burst of rapid ventricular pacing was delivered at about 80% of the cycle length. During a follow-up period of 5 +/- 2 months (range, 3 to 8) two to 291 successful interventions of antitachycardia pacing were counted from diagnostic data which had been collected by the pulse generator during the course of treatment. When the antitachycardia pacemaker failed to terminate VT, the AICD was activated. In the individual case, between 0 and 41 discharges of the AICD were delivered. The high pulse energy of the AICD did not damage the antitachycardia pacemaker; no interference of the two devices was observed. Future antitachycardia systems should be more flexible with regard to detection and termination modes, combining antitachycardia pacing with back-up defibrillation.

Internal cardiac defibrillation threshold: effects of acute ischemia

The influence of myocardial ischemia on defibrillation success was studied using two different lead orientations in halothane-anesthetized pigs. Ischemia was induced by ligating the left anterior descending artery in its distal third. Controls had loosely tied ligatures placed around the artery at the same site. Ventricular fibrillation was induced by electrical stimulation 30 minutes after coronary artery ligation. Defibrillation used a single truncated pulse of approximately 6 ms duration passed to either: a transvenous electrode catheter (Medtronic, 6880) with the cathode in the apex of the right ventricle and the anode in the superior vena cava-atrial junction region, or the cathode in the apex of the right ventricle and a mesh plaque on the epicardium of the basal lateral left ventricle as anode. Ten seconds after the onset of ventricular fibrillation, defibrillation was attempted with increasing incremental energies until defibrillation was achieved. Fibrillation episodes were repeated at 15-minute intervals until the minimum first shock was successful in defibrillating the animal (i.e., defibrillation threshold). The number of animals successfully defibrillated with a minimum energy above or below 30 J was not different between normal and ischemic animals for either electrode configuration (i.e., 3 out of 20 vs 1 out of 13 for the catheter and 5 out of 6 vs 6 out of 7 for the epicardial plaque, respectively). Also, the cumulative percent success as a function of defibrillation energy was similar in both the normal and ischemic groups. There was a significant reduction in the minimum energy necessary for defibrillation when passing current between the right ventricular apex and the left ventricular epicardial plaque. The present results indicate that, despite differences in lead orientations, acute ischemia in the anesthetized pig does not appear to influence defibrillation success.

Electrocardiographic changes after cardioversion of ventricular arrhythmias

To evaluate rhythm and QRS-T changes after cardioversion of induced ventricular arrhythmias, 56 patients underwent continuous three-lead and serial 12-lead electrocardiographic monitoring for 15 min after 77 cardioversions. Fifty patients were cardioverted externally and nine internally with an implanted automatic cardioverter/defibrillator. Initial energy for external cardioversion was 200 Wsec in 57 of 64 arrhythmia episodes. Two hundred watt-seconds of energy effectively terminated 41 of 44 episodes of ventricular tachycardia and six of 13 episodes of ventricular fibrillation (p less than .001). Early bradycardia (mean cycle length greater than or equal to 1200 msec during the first 5 sec) occurred after 17 of 64 external and two of 13 internal cardioversions (p = NS) in a total of 16 patients. Bradycardia persisted at 10 sec after cardioversion in nine patients. Early bradycardia was associated with the need for multiple cardioversions to terminate the arrhythmia (six of 10 multiple cardioversions vs 13 of 67 single cardioversions, p less than .05) and the presence of inferior myocardial infarction (eight of 16 patients with vs eight of 40 patients without inferior infarction, p less than .05). Supraventricular tachycardia (cycle length less than or equal to 500 msec) occurred after 19 of 64 external and six of 13 internal cardioversions (p = NS). Nonsustained ventricular tachycardia (4 to 40 beats) was observed after seven external cardioversions, with three episodes lasting 3 sec or more.(ABSTRACT TRUNCATED AT 250 WORDS)

The implanted defibrillator: relation of defibrillating lead configuration and clinical variables to defibrillation threshold

Forty-two defibrillating lead systems for the automatic implantable defibrillator were implanted and tested in 41 patients. Two basic lead configurations were used: 1) spring-patch, consisting of a transvenous superior vena cava spring electrode as the anode and an apical or left lateral ventricular patch electrode (either small [13.9 cm2] or large [27.9 cm2]) as the cathode; and 2) patch-patch, consisting of an anterior right ventricular patch as the anode and a posterior left ventricular patch as the cathode. Of the 42 lead systems, 10 were spring-patch and 32 were patch-patch combinations. The defibrillation threshold for the patch-patch combinations (9.8 +/- 6.5 J, mean +/- standard deviation) was significantly (p less than 0.01) lower than that for the spring-patch combinations (19.1 +/- 10.3 J). Subgroup analysis revealed the lowest defibrillation thresholds for patch-patch combinations with at least one large patch. Total surface area of defibrillating leads was strongly negatively correlated with the defibrillation threshold (p less than 0.005). Analysis of the relation of clinical variables to defibrillation threshold revealed that only amiodarone therapy was independently associated with a significantly (p less than 0.05) higher defibrillation threshold. Thus, surface area of the defibrillating leads is a critical determinant of the defibrillation threshold for the implanted defibrillator. Patch-patch lead systems with at least one large patch may provide an increased safety margin for defibrillation. Conversely, amiodarone therapy is associated with higher defibrillation thresholds and may decrease the margin of safety.

The automatic implantable cardioverter-defibrillator: an overview

The automatic implantable cardioverter-defibrillator continuously monitors the heart, identifies malignant ventricular tachyarrhythmias and then delivers electrical countershock to restore normal rhythm. There are two defibrillating electrodes which are also used for waveform analysis; one is located in the superior vena cava and the other is placed over the cardiac apex. A third bipolar right ventricular electrode is used for rate counting and R wave synchronization. When ventricular fibrillation occurs, a 25 J pulse is delivered; when ventricular tachycardia faster than the preset rate is detected, the discharge is R wave-synchronized. The clinical evaluation study of this therapeutic method began in February 1980 in patients with recurrent refractory life-threatening ventricular tachyarrhythmias. So far, the device has been implanted in nearly 500 patients with a follow-up period of up to 59 months. The risks and complications associated with this treatment were found to be moderate. Actuarial analysis has demonstrated significant impact on the survival rate of the patients receiving implants with 1 year arrhythmic mortality rate reduced to 2% or less in all groups analyzed. The available data indicate that the automatic cardioverter-defibrillator can reliably identify and correct potentially lethal ventricular tachyarrhythmias, leading to a substantial improvement in survival in properly selected high risk patients.

Out-of-hospital automatic cardioversion of ventricular tachycardia

A 42 year old man who survived sudden cardiac death was treated with an automatic implantable cardioverter/defibrillator. After a 5 month symptom-free interval, the patient received two internal discharges in the conscious state while wearing an ambulatory electrocardiographic recorder. Analysis of the tape revealed that both discharges were activated by two bursts of polymorphous ventricular tachycardia, the first one occurring at the end and the second at the onset of episodes of slow, hemodynamically stable monomorphous ventricular tachycardia. This case illustrates the reliability of the automatic implantable cardioverter/defibrillator as an antiventricular tachycardia device and the problem posed by its exposure to nonsustained ventricular tachycardia.

Activation of the right ventricular apical electrogram during ventricular tachycardia: suitability for synchronizing intracavitary cardioversion

An intravascular catheter positioned in the right ventricular apex has been used for intracavitary cardioversion in patients with recurrent ventricular tachycardia. We examined the timing of the right ventricular apical electrogram during sinus rhythm and ventricular tachycardia (VT) in order to determine if this signal could be used to synchronize the delivery of a countershock. Sixty-three distinct morphologies of VT were observed in 33 patients undergoing electrophysiologic testing with programmed stimulation. Regardless of VT morphology or site of origin, the bipolar right ventricular electrogram always occurred within the peripheral QRS complex during ventricular tachycardia. Relative timing occurred within the QRS ranging from the initial 13% of the QRS to the last 12%. When all episodes of VT were examined, the timing of the right ventricular electrogram did not correlate linearly with the peak of the ECG, but the right ventricular electrogram occurred within 60 ms of the peak ECG in 83% of episodes of ventricular tachycardia. In one case of arrhythmogenic right ventricular dysplasia, the right ventricular electrogram occurred 160 ms after the peak ECG in ventricular tachycardia, a time when delivery of a countershock may have precipitated ventricular fibrillation. Six of these patients underwent cardioversion utilizing an intracavitary catheter and external generator. Acceleration of VT, or conversion to ventricular fibrillation, occurred following two of 27 shocks (7.4%). The right ventricular electrogram occurred the latest within the QRS complex in the two patients who developed acceleration of the tachycardia.(ABSTRACT TRUNCATED AT 250 WORDS)

Clinical experience, complications, and survival in 70 patients with the automatic implantable cardioverter/defibrillator

Seventy patients received the automatic implantable defibrillator, five original devices and 72 modified second-generation devices using only bipolar rate sensing and delivering an R wave synchronous cardioverting/defibrillating shock, for either ventricular tachycardia or fibrillation. The primary clinical arrhythmia was sustained ventricular tachycardia in 32 patients, ventricular fibrillation in 20 patients, and both ventricular tachycardia and fibrillation in 18 patients. Before implantation of the device the patients had survived 3.1 +/- 2.3 arrhythmic episodes, including 1.9 +/- 1.7 cardiac arrest, and had received 4.0 +/- 2.1 antiarrhythmic drugs without improvement. Sixty-eight patients ultimately received devices. After a follow-up period of 8.9 +/- 7.7 months (range 1 to 33), 37 patients received a total of 463 discharges. Inability to determine the precise reason for most discharges and the unpleasant nature of the discharges were the major clinical problems encountered. Complications included postoperative death (one patient), lead problems (six patients), inadequate energy requiring explanation (two patients), and pocket infection (one patient. Life-table analysis revealed 6 and 12 month cardiovascular survival of 95.0% and 89.9% and sudden death survival of 98.2%. In our experience, survival with the automatic implantable cardioverter/defibrillator exceeds that with other forms of therapy.